Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach

NCT00985192 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00985192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
May 31, 2014
Enrollment
49 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer